Corrona Registries: Rheumatoid Arthritis

Corrona US RA Registry Site Map

This registry collects data from both physicians and patients at the time of a regular office visit.

  • The Corrona RA registry is the largest RA real world prospective cohort study in the world. We collect data from both physicians and patients at the time of a clinical encounter.
  • >40,000 patients enrolled and >130,000 patient years of longitudinal follow-up; Additionally, personal health information on approximately 10,000 patients (subject to HIPAA requirements), allowing studies to link to other data sets.
  • Physician data collected at visit to calculate clinical disease activity measures such as CDAI, DAS-28 and HAQ scores.
  • The Corrona RA registry has provided major contributions to the following:
    • Greater understanding of the comparative effectiveness and safety of biologic or small molecule DMARD drugs.
    • Effects of biologic or small molecule DMARD drugs on risk of cardiovascular, infectious, and malignancy outcomes.
    • Biologic and small molecule DMARD prescribing patterns, including the real world impact of the ACR RA DMARD guidelines on clinical care provided by rheumatologists.

Key facts about our RA Registry

  • Currently >23,000 RA patients being followed in 2015 (>50% on a biologic DMARD) with a mean length of follow-up of 4.41 years (median 3.46 years). Ability to query data on all products in the market space is unique to the Corrona registry.
  • 80 rheumatology sites, 12 university sites, 68 private practice/affilliated sites.
  • Open enrollment for biologic DMARD or targeted synthetic DMARDs (tofacitinib).
  • Follow-up visits every 6 months.
  • Physician and patient questionnaires completed at follow-up visits every 6 months.
  • Quality control for completion of critical data elements.

Enrollment and support of the Corrona RA Registry

Corrona is currently accepting new sites that have clinical research experience and supporting infrastructure.
Please contact us at